Did some digging, this is what I could find on long acting stimulant comparisons on medscape, unfortunately there was a lack of articles comparing head-to-head pharmcokinetic differences in more depth (Cmax, Tmax, t2, AUC, etc.):
Options for the Management of Attention Deficit/Hyperactivity (ADHD)
New-Generation Long-Acting Stimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder
Concerta (Methylphenidate OROS Tablets)
Metadate CDThe tablet has an outer coating of methylphenidate that is absorbed rapidly after ingestion, providing approximately 20% of the dose immediately.[1–6] After the coating has dissolved, penetration of gastric fluid through the semipermeable outer membrane expands an osmotic agent in the push layer of the core, causing it to slowly force the methylphenidate contained in the core out a laser-drilled opening in the tablet over 12 hours.
Following oral doses of Concerta 18 mg, mean methylphenidate plasma concentrations increased rapidly over the first 2 hours, followed by a slower increase for the next 3-4 hours followed by a gradual decline thereafter. Peak concentrations were reached at 6-8 hours and gradually declined to baseline by 24 hours (Figure 1). This pharmacokinetic profile, with lower peak concentrations than either the 3-times-daily immediate-release or sustained-release formulations, eliminates the large fluctuations associated with these older preparations, securing continued clinical control without the well known "peaks and valleys" of the immediate-release formulation.
Ritalin LAMetadate CD® is a Diffucaps® formulation, a mix of 30% immediate-release beads and 70% delayed-release beads that deliver methylphenidate over approximately an 8 to 10 hour period. The delayed-release beads dissolve more slowly and are typically absorbed in the intestine.
Focalin XRCoated beads are designed to release drug in two relatively equal amounts over approximately an 8 to 10 hour period. With the spheroidal oral drug absorption system (SODAS®) technology used for this preparation, 50% of the beads are immediate-release and 50% are enteric-coated delayed-release beads that dissolve more slowly in the intestine. This provides an initial peak serum concentration shortly after administration and a second peak at 4 hours.
DaytranaDexmethylphenidate, the active d-enantiomer of methylphenidate, is also available in a once-daily capsule formulation (Focalin XR®) which uses SODAS® technology. This product provides drug release over an 8 to 12 hour period, with an initial peak at approximate 1½ hrs and a second peak at 6.5 hrs (range 4.5–7 hrs).
Adderall XRThe Daytrana® transdermal patch was approved by the Food and Drug Administration in 2006. The three layer patch consists of a polyester/ethylene vinyl acetate laminate film backing, an adhesive layer that contains methylphenidate combined with acrylic and silicone adhesives, and a protective liner that is removed prior to application. Dose varies by patch size. The patch is designed to be worn for 9 hours to provide 12 hours of symptom control, but adjustment of wear times to tailor duration remains the primary reason for selecting this formulation.
VyvanseThe branded mixed dextroamphetamine salts product, Adderall XR®, uses Microtrol® technology to provide an 8–10 hour duration.[1–3] Half of the beads within the capsule are immediate-release; the remaining beads are coated with a polymer that degrades in the higher pH of the intestine which prolongs absorption and results in sustained drug effect. Generic versions of mixed dextroamphetamine salts are available with similar absorption characteristics.
In 2008, a prodrug of dextroamphetamine, lisdexamfetamine (Vyvanse®), was introduced in the US. The prodrug is inactive until hydrolyzed in the blood and liver to dextroamphetamine and the amino acid l-lysine.The product was designed to reduce the potential for abuse, but also provides a prolonged duration of action (up to 13 hours in some patients)